ATE300312T1 - Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln - Google Patents

Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln

Info

Publication number
ATE300312T1
ATE300312T1 AT99902800T AT99902800T ATE300312T1 AT E300312 T1 ATE300312 T1 AT E300312T1 AT 99902800 T AT99902800 T AT 99902800T AT 99902800 T AT99902800 T AT 99902800T AT E300312 T1 ATE300312 T1 AT E300312T1
Authority
AT
Austria
Prior art keywords
hbsag particles
particles
delivery
immunogenic molecules
hbsag
Prior art date
Application number
AT99902800T
Other languages
German (de)
English (en)
Inventor
Jorg Reimann
Yechezkel Barenholz
Dvorah Diminsky
Reinhold Schirmbeck
Original Assignee
Yissum Res Dev Co
Reimann Joerg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Reimann Joerg filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE300312T1 publication Critical patent/ATE300312T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99902800T 1998-02-03 1999-01-29 Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln ATE300312T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7347698P 1998-02-03 1998-02-03
PCT/IL1999/000060 WO1999039736A2 (en) 1998-02-03 1999-01-29 DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES

Publications (1)

Publication Number Publication Date
ATE300312T1 true ATE300312T1 (de) 2005-08-15

Family

ID=22113916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902800T ATE300312T1 (de) 1998-02-03 1999-01-29 Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln

Country Status (9)

Country Link
EP (1) EP1053018B1 (enExample)
JP (1) JP4480267B2 (enExample)
AT (1) ATE300312T1 (enExample)
AU (1) AU755957B2 (enExample)
CA (1) CA2319599C (enExample)
DE (1) DE69926342T2 (enExample)
DK (1) DK1053018T3 (enExample)
ES (1) ES2242376T3 (enExample)
WO (1) WO1999039736A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ912000A0 (en) * 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
DE10106235A1 (de) * 2001-02-10 2002-08-22 Bosch Gmbh Robert Wischarm
KR20060015534A (ko) 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
PL1802746T3 (pl) 2004-10-27 2011-10-31 Crucell Switzerland Ag Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B
JP2009120532A (ja) * 2007-11-14 2009-06-04 Osaka Univ 糖及び糖鎖認識機構を利用する物質送達用及びバイオイメージング用バイオナノカプセル

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
JP2001526688A (ja) * 1997-05-19 2001-12-18 メルク エンド カンパニー インコーポレーテッド オリゴヌクレオチドアジュバント

Also Published As

Publication number Publication date
JP4480267B2 (ja) 2010-06-16
EP1053018B1 (en) 2005-07-27
WO1999039736A2 (en) 1999-08-12
DK1053018T3 (da) 2005-08-15
AU755957B2 (en) 2003-01-02
CA2319599A1 (en) 1999-08-12
ES2242376T3 (es) 2005-11-01
AU2297399A (en) 1999-08-23
WO1999039736A3 (en) 1999-09-23
DE69926342D1 (de) 2005-09-01
DE69926342T2 (de) 2006-01-12
JP2002502828A (ja) 2002-01-29
CA2319599C (en) 2011-04-19
EP1053018A2 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
CA2182303A1 (fr) Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
ATE377076T1 (de) Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
AR248426A1 (es) Produccion de particulas incorporadas a un virus vegetal que contiene un peptido antigenico, con el fin de preparar una vacuna de virus animal.
GEP20002180B (en) Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
EP0757717A4 (en) PAPILLOMAVIRUS VACCINE
DE69838383D1 (de) Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
EP0994721A4 (en) NERVOUS GROWTH FACTOR AS A VACCINE ADDITIVE
SE8303211L (sv) Rena teichomycin a?712 singelfaktorer 1,2,3,4 och 5 och sett for deras framstellning
ATE268384T1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
DE69926342D1 (de) Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln
MXPA01005509A (es) Alimento para bebes estimulantes del crecimiento del timo.
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DK1146906T3 (da) Mukosalt afgivelsessystem
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
TW200504216A (en) Immunization of fish with plant-expressed recombinant proteins
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
EP0745386A4 (en) SECRETORIC RECOMBINANT BCG VACCINE AGAINST AIDS
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
WO2001043769A3 (en) Antigen delivery

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053018

Country of ref document: EP

REN Ceased due to non-payment of the annual fee